Extended Human Acceptability Study of Chloroquine/Primaquine Plus Diformyl DDS.
Rept. no. 8,
OKLAHOMA STATE PENITENITARY MCALESTER
Pagination or Media Count:
Fifty healthy adult male volunteer subjects were given either chloroquineprimaquine plus placebo or chloroquineprimaquine plus 200 mg. WR-6798 in identical appearing capsules. Medication was given orally once weekly for 16 weeks and on the day following each dose of medication blood and urine specimens were collected for chloroquine and sulfane concentration levels, alkaline phosphatase and BUN. These results demonstrated that chloroquineprimaquine plus 200 mgm of WR-6798 is associated with an increased incidence of methemoglobinemia but the data does not define the mechanism by which chloroquineprimaquine plus WR-6798 causes methemoglobinemia. Other observed and measured parameters varied sporadically and could not be directly related to drug administration. Author